2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis

Estimating the Prevalence of Cardiac Amyloidosis in Old Patients with Heart Failure—Barriers and Opportunities for Improvement: The PREVAMIC Study

“…Similarly, other recently developed tools such as scores performed in heart failure with a preserved left ventricular ejection fraction or machine-learning models that identify patients at a high risk of amyloidosis could be of benefit to our patients [ 31 , 32 , 33 ]. Lastly, there are clinical pathways implemented in other countries with excellent results [ 34 , 35 , 36 ]. These programs, focused on multidisciplinary collaboration, have shown increased awareness of the disease among physicians, improvement in diagnostic delay, and better access to amyloid specialists.…”

Assessment of the patient with heart failure symptoms and risk factors: A guide for the non‐cardiologist

“…An ECG may be helpful in the following scenarios: In patients with symptoms and an EF of 50% or higher, the Amer- Decision Pathway, 23 which has detailed information regarding the diagnosis of HFpEF, including mimics of HFpEF. In this document, they highlight a couple of scoring systems that have been published to estimate the likelihood of a clinical diagnosis of HFpEF.…”

“…Dietary guidance, exercise (including cardiac rehabilitation for patients with HFrEF), monitoring blood pressure, and being aware of symptoms and signs of worsening volume status can all be effective tools for patients to self-manage their heart failure. 23,28 Meta-analyses have shown that interventions focused on improving heart failure self-care significantly reduce the risk of hospitalization, prolong mortality and improve quality of life. [29][30][31][32][33]…”

“…65,66 Although treatments for obesity are not often considered a part of guideline-directed medical therapy for heart failure, obesity has a substantial impact on the development and management of heart failure, and directly addressing this co-morbidity should be prioritized. 23 While there are currently limited data on these therapies specifically in patients with heart failure, two ongoing trials of glucagon-like peptide-1 agonists in patients with obesity and HFpEF should provide important insights (https://clinicaltrials.gov: NCT04847557, NCT04788511).…”

Early Diagnosis and Treatment Key for Cardiac Amyloidosis Outcomes

“…To help cardiologists navigate this rapidly evolving landscape, the American College of Cardiology (ACC) published an expert consensus decision pathway on cardiac amyloidosis earlier this year. 1 The pathway is the product of a multidisciplinary roundtable of experts convened by the ACC in 2022. It emphasizes the importance of screening for patients with suspected amyloidosis to facilitate early treatment and a multidisciplinary team-based approach to care.…”